Mary Roeloffs is a Forbes breaking news reporter covering pop culture.Aug 26, 2026, 11:53am EDTToplineThe Food and Drug Administration has approved a new medication for pancreatic cancer patients called daraxonrasib, a once-daily pill that blocks RAS proteins and has been shown to double patient survival time when compared to standard chemotherapy treatment.A sign for the Food And Drug Administration is seen outside of the headquarters in White Oak, Maryland.Getty ImagesKey FactsThe medication, made by the biotech company Revolution Medicines and sold under the brand name Rasonque, was approved six months ahead of schedule on Wednesday as one of few treatment options available for pancreatic cancer, the fourth leading cause of cancer deaths in the United States. This is a developing story and will be updated. LOADING VIDEO PLAYER...FORBES’ FEATURED VideoExplore Topic
FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque
Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.
131 words~1 min read
